AbCellera Biologics (NASDAQ:ABCL) Upgraded by Leerink Partnrs to Strong-Buy Rating

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) was upgraded by equities research analysts at Leerink Partnrs to a "strong-buy" rating in a research note issued to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for AbCellera Biologics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) EPS and FY2026 earnings at ($0.28) EPS.

ABCL has been the topic of several other reports. Leerink Partners began coverage on shares of AbCellera Biologics in a research report on Monday. They issued an "outperform" rating and a $5.00 target price on the stock. Truist Financial lowered their target price on AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Finally, KeyCorp lifted their target price on AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, AbCellera Biologics has a consensus rating of "Buy" and an average target price of $7.50.

AbCellera Biologics Stock Down 3.4%

NASDAQ:ABCL traded down $0.15 during trading hours on Monday, reaching $4.11. 1,718,898 shares of the company's stock were exchanged, compared to its average volume of 3,466,646. The company has a market capitalization of $1.23 billion, a P/E ratio of -7.31 and a beta of 0.62. AbCellera Biologics has a 12 month low of $1.89 and a 12 month high of $4.33. The business's 50-day simple moving average is $2.79 and its two-hundred day simple moving average is $2.76.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.02. The firm had revenue of $4.24 million during the quarter, compared to analysts' expectations of $7.12 million. AbCellera Biologics had a negative net margin of 737.56% and a negative return on equity of 15.98%. As a group, sell-side analysts anticipate that AbCellera Biologics will post -0.59 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Stratos Wealth Advisors LLC bought a new position in AbCellera Biologics during the first quarter valued at approximately $27,000. DKM Wealth Management Inc. bought a new position in AbCellera Biologics during the fourth quarter valued at approximately $29,000. Janney Montgomery Scott LLC bought a new position in AbCellera Biologics during the first quarter valued at approximately $29,000. AssuredPartners Investment Advisors LLC bought a new position in AbCellera Biologics during the first quarter valued at approximately $34,000. Finally, Balyasny Asset Management L.P. bought a new stake in AbCellera Biologics in the fourth quarter worth $40,000. Hedge funds and other institutional investors own 61.42% of the company's stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.